Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Caplacizumab Frontline Added to Therapeutic Plasma Exchange and Immunosuppression Prevents Unfavorable Outcomes in Immune-Mediated TTP: An International Real-World Study of the TTP-IWG (The Capla 500 Project)

Blood (2023) 142 (Supplement 1): 2636.

https://doi.org/10.1182/blood-2023-179316

Published: 2023

Journal Articles

Rare germline complement factor H variants in patients with paroxysmal nocturnal hemoglobinuria

Pedro Henrique Prata, Jacques-Emmanuel Galimard, Flore Sicre de Fontbrune, Anna Duval, Paula Vieira Martins, Stephane Roncelin, Pierre-Édouard Debureaux, Anne-Claire Lepretre, Lise Larcher, Rudy Birsen, Ygal Benhamou, Jean Soulier, Gérard Socié, Véronique Fremeaux-Bacchi, Régis Peffault de Latour

Blood (2023) 141 (15): 1812–1816.

https://doi.org/10.1182/blood.2022017019

Published: 2023

Includes: Supplemental data

Journal Articles

Immune-mediated thrombotic thrombocytopenic purpura following COVID-19 vaccination

Adrien Picod, Jean-Michel Rebibou, Antoine Dossier, Bérengère Cador, David Ribes, Claire Vasco-Moynet, Caroline Stephan, Mathieu Bellal, Alain Wynckel, Pascale Poullin, Edwige Péju, Laure Ricard, Jean-Emmanuel Kahn, Raïda Bouzid, Ygal Benhamou, Bérangère Joly, Agnès Veyradier, Paul Coppo

Blood (2022) 139 (16): 2565–2569.

https://doi.org/10.1182/blood.2021015149

Published: 2022

Journal Articles

A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP

Blood (2021) 137 (6): 733–742.

https://doi.org/10.1182/blood.2020008021

Published: 2021

Includes: Supplemental data

Journal Articles

Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura

Blood (2020) 136 (3): 353–361.

https://doi.org/10.1182/blood.2019004221

Published: 2020

Includes: Supplemental data

Journal Articles

Immune thrombotic thrombocytopenic purpura in older patients: prognosis and long-term survival

Blood (2019) 134 (24): 2209–2217.

https://doi.org/10.1182/blood.2019000748

Published: 2019

Includes: Supplemental data

Journal Articles

Open ADAMTS13 Conformation in Immune-Mediated Thrombotic Thrombocytopenic Purpura Is Induced By Anti-ADAMTS13 Autoantibodies and Corresponds with an Ongoing ADAMTS13 Pathology

Blood (2018) 132 (Supplement 1): 222.

https://doi.org/10.1182/blood-2018-99-113762

Published: 2018

Journal Articles

Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura

Blood (2018) 132 (20): 2143–2153.

https://doi.org/10.1182/blood-2018-04-840090

Published: 2018

Includes: Supplemental data

Journal Articles

Efficacy of Eculizumab in Gemcitabine-Induced Thrombotic Microangiopathy: Experience of the French Thrombotic Microangiopathies Reference Centre

Maximilien Grall, MD, Francois Provôt, MD, Jean-Philippe Coindre, MD, Claire Pouteil-Noble, MD PhD, Dominique Guerrot, MD PhD, Ygal Benhamou, MD, Dominique Bordessoule, MD PhD, Agnes Veyradier, MD PhD, Paul Coppo, MD PhD, Steven Grange, MD

Blood (2016) 128 (22): 136.

https://doi.org/10.1182/blood.V128.22.136.136

Published: 2016

Journal Articles

Thrombotic Thrombocytopenic Purpura Misdiagnosed As Autoimmune Cytopenia: Causes of Diagnostic Errors and Consequence on Outcome. Experience of the French Thrombotic Microangiopathies Reference Centre

Maximilien Grall, MD, Ygal Benhamou, MD, Elie Azoulay, MD PhD, Eric Mariotte, MD, Lionel Galicier, MD, Steven Grange, MD, Virginie Barbay, MD, Dominique Bordessoule, MD PhD, Agnes Veyradier, MD PhD, Paul Coppo, MD PhD

Blood (2016) 128 (22): 3730.

https://doi.org/10.1182/blood.V128.22.3730.3730

Published: 2016

Journal Articles

Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura

Miguel Hie, Julie Gay, Lionel Galicier, François Provôt, Claire Presne, Pascale Poullin, Guy Bonmarchand, Alain Wynckel, Ygal Benhamou, Philippe Vanhille, Aude Servais, Dominique Bordessoule, Jean-Philippe Coindre, Mohamed Hamidou, Jean-Paul Vernant, Agnès Veyradier, Paul Coppo, the French Thrombotic Microangiopathies Reference Centre

Blood (2014) 124 (2): 204–210.

https://doi.org/10.1182/blood-2014-01-550244

Published: 2014

Includes: Supplemental data

Journal Articles

Assessment Of Endothelial Damage and Cardiac Injury In a Mouse Model Mimicking Thrombotic Thrombocytopenic Purpura

Maelle Le Besnerais, Julie Favre, PhD, Cecile V. Denis, PhD, Bernard Lenormand, Paul Mulder, PhD, Lionel Nicol, PhD, Agnes Veyradier, MD PhD, Alexandra Schiviz, DVM, David G Motto, MD, PhD, Herve Levesque, MD PhD, Paul Coppo, MD PhD, Vincent Richard, PhD, Ygal Benhamou, MD

Blood (2013) 122 (21): 447.

https://doi.org/10.1182/blood.V122.21.447.447

Published: 2013

Journal Articles

Preemptive Rituximab Infusions Efficiently Prevent Relapses In Acquired Thrombotic Thrombocytopenic Purpura. Experience Of The French Thrombotic Microangiopathies Reference Center

Miguel HIE, MD, Julie Gay, MD, Lionel Galicier, MD, Francois Provot, Sandrine Malot, Pascale Poullin, MD, Guy Bonmarchand, MD, Alain Wynckel, MD, Ygal Benhamou, MD, Philippe Vanhille, Dominique Bordessoule, MD, PhD, Jean-Paul Vernant, Agnes Veyradier, MD PhD, Paul Coppo, MD PhD

Blood (2013) 122 (21): 448.

https://doi.org/10.1182/blood.V122.21.448.448

Published: 2013

Journal Articles

Development and Validation of a Predictive Model for Death in Acquired Severe ADAMTS13 Deficiency-Associated Idiopathic Thrombotic Thrombocytopenic Purpura: The French TMA Reference Center Experience

Ygal Benhamou, Cyrielle Assie, Pierre-Yves Boelle, Marc Buffer, Rana Grillberger, PharmD, Sandrine Malot, Dominique Bordessoule, Lionel Galicier, MD, Elie Azoulay, MD, PhD, Hanspeter Rottensteiner, PhD, Agnes Veyradier, Paul Coppo

Blood (2011) 118 (21): 2229.

https://doi.org/10.1182/blood.V118.21.2229.2229

Published: 2011

NARROW

Caplacizumab Frontline Added to Therapeutic Plasma Exchange and Immunosuppression Prevents Unfavorable Outcomes in Immune-Mediated TTP: An International Real-World Study of the TTP-IWG (The Capla 500 Project)

Rare germline complement factor H variants in patients with paroxysmal nocturnal hemoglobinuria

Immune-mediated thrombotic thrombocytopenic purpura following COVID-19 vaccination

A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP

Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura

Immune thrombotic thrombocytopenic purpura in older patients: prognosis and long-term survival

Open ADAMTS13 Conformation in Immune-Mediated Thrombotic Thrombocytopenic Purpura Is Induced By Anti-ADAMTS13 Autoantibodies and Corresponds with an Ongoing ADAMTS13 Pathology

Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura

Efficacy of Eculizumab in Gemcitabine-Induced Thrombotic Microangiopathy: Experience of the French Thrombotic Microangiopathies Reference Centre

Thrombotic Thrombocytopenic Purpura Misdiagnosed As Autoimmune Cytopenia: Causes of Diagnostic Errors and Consequence on Outcome. Experience of the French Thrombotic Microangiopathies Reference Centre

Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura

Assessment Of Endothelial Damage and Cardiac Injury In a Mouse Model Mimicking Thrombotic Thrombocytopenic Purpura

Preemptive Rituximab Infusions Efficiently Prevent Relapses In Acquired Thrombotic Thrombocytopenic Purpura. Experience Of The French Thrombotic Microangiopathies Reference Center

Development and Validation of a Predictive Model for Death in Acquired Severe ADAMTS13 Deficiency-Associated Idiopathic Thrombotic Thrombocytopenic Purpura: The French TMA Reference Center Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only